Streetbeat News

WXIBF

Wuxi Biologics (Cayman) Inc.

https://www.wuxibiologics.com/

CEO

Zhisheng Chen

Industry

Testing Laboratories

Open

2.25

Mkt cap

9.3B

Volume

200

High

2.25

P/E Ratio

28.13

52-wk high

6.60

Low

2.25

Div yield

N/A

52-wk low

1.30

U.S. intelligence officials have accused WuXi AppTec Co Ltd (OTC:WXIBF), a Chinese pharmaceutical company, of illegally transferring U.S. intellectual property to Beijing. This revelation was made during a classified briefing to senators, amid broader concerns over Chinese companies' involvement in activities against U.S. national security interests. WuXi AppTec denies the allegations, emphasizing their commitment to safeguarding client data. The U.S. is considering legislation to restrict government funds to Chinese firms engaged in such activities.

Portfolio Pulse from Benzinga Neuro

March 28, 2024 | 7:13 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.